Merus N.V. Common Shares
MRUS Real Time Price USDRecent trades of MRUS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MRUS's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Antibody that binds erbb-2 and erbb-3 Nov. 12, 2024
-
Patent Title: Methods and means for the production of ig-like molecules Oct. 22, 2024
-
Patent Title: Bispecific igg antibodies as t cell engagers Aug. 13, 2024
-
Patent Title: Pd-1 binding domains May. 28, 2024
-
Patent Title: Multivalent antibody Apr. 09, 2024
-
Patent Title: Binding molecules that inhibit cancer growth Mar. 26, 2024
-
Patent Title: Methods and means for the production of ig-like molecules Mar. 12, 2024
-
Patent Title: Antibody producing non-human animals Mar. 12, 2024
-
Patent Title: Clec12axcd3 bispecific antibodies and methods for the treatment of disease Jan. 16, 2024
-
Patent Title: Methods of treating a subject having an egfr-positive and/or erbb-3-positive tumor Nov. 21, 2023
-
Patent Title: Antibody producing non-human animals Oct. 17, 2023
-
Patent Title: Human cd3 binding antibody Aug. 29, 2023
-
Patent Title: Antibodies that modulate a biological activity expressed by a cell Aug. 22, 2023
-
Patent Title: Binding molecules that bind cd137 and pd-l1 Jun. 27, 2023
-
Patent Title: Binding molecules that modulate a biological activity expressed by a cell Jun. 06, 2023
-
Patent Title: Antibody producing non-human animals Jan. 24, 2023
-
Patent Title: Antibody producing non-human animals Sep. 20, 2022
-
Patent Title: Generation of binding molecules Aug. 09, 2022
-
Patent Title: Antibody that binds erbb-2 and erbb-3 Mar. 22, 2022
-
Patent Title: Antibody producing non-human animals Feb. 01, 2022
-
Patent Title: Antibody producing non-human mammals Apr. 06, 2021
-
Patent Title: Recombinant production of mixtures of antibodies Mar. 02, 2021
-
Patent Title: Antibodies that bind egfr and erbb3 Nov. 24, 2020
-
Patent Title: Methods and means for the production of ig-like molecules Aug. 25, 2020
-
Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Jun. 02, 2020
-
Patent Title: Generation of binding molecules May. 12, 2020
-
Patent Title: Recombinant production of mixtures of antibodies Dec. 17, 2019
-
Patent Title: Bispecific igg antibodies as t cell engagers Jul. 23, 2019
-
Patent Title: Methods and means for the production of ig-like molecules Jul. 02, 2019
-
Patent Title: Methods and means for the production of ig-like molecules Jun. 25, 2019
-
Patent Title: Human cd3 binding antibody Apr. 23, 2019
-
Patent Title: Antibody producing non-human mammals Apr. 24, 2018
-
Patent Title: Antibody producing non-human mammals Apr. 17, 2018
-
Patent Title: Human cd3 binding antibody Mar. 13, 2018
-
Patent Title: Generation of binding molecules Mar. 06, 2018
-
Patent Title: Antibody producing non-human mammals Sep. 19, 2017
-
Patent Title: Methods and means for the production of ig-like molecules Sep. 12, 2017
-
Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Aug. 22, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of MRUS in WallStreetBets Daily Discussion
Recent insights relating to MRUS
Recent picks made for MRUS stock on CNBC
ETFs with the largest estimated holdings in MRUS
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MRUS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.